ADJUVANT COMPARISON AND CHARACTERIZATION

点击翻译按钮获取中文摘要

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms and have potential for a given antigen and/or disease target. Contractors supported through the ACC program will be expected to: 1) collaborate with each other, including using standardized protocols or endpoint assays; 2) screen additional adjuvants at the direction of NIAID; and 3) share both positive and negative results in order to help guide basic research and vaccine development activities within the program and across the broader scientific community. In addition, data generated from ACC-supported studies will be made publicly available, enabling the rational selection of adjuvants and the future development of more effective vaccines against infectious diseases, and/or new vaccines to treat allergic or autoimmune diseases.